HSS(MD) 29/2021 – COVID-19 THERAPEUTIC ALERT – INHALED BUDESONIDE FOR ADULTS (50 YEARS AND OVER) WITH COVID-19

 Recommendation 

Inhaled budesonide is not currently being recommended as standard of care but can be considered (off-label) on a case-by-case basis for symptomatic COVID-19 positive patients aged 65 and over, or aged 50 or over with co-morbidities, in line with the published Interim Position Statement.